JP2016500513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500513A5 JP2016500513A5 JP2015532967A JP2015532967A JP2016500513A5 JP 2016500513 A5 JP2016500513 A5 JP 2016500513A5 JP 2015532967 A JP2015532967 A JP 2015532967A JP 2015532967 A JP2015532967 A JP 2015532967A JP 2016500513 A5 JP2016500513 A5 JP 2016500513A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- active ingredient
- conjugate
- composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 239000004480 active ingredient Substances 0.000 claims 13
- 239000002872 contrast media Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical group [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120104173 | 2012-09-19 | ||
| KR20120104144 | 2012-09-19 | ||
| KR10-2012-0104144 | 2012-09-19 | ||
| KR10-2012-0104173 | 2012-09-19 | ||
| KR20120109216 | 2012-09-28 | ||
| KR10-2012-0109216 | 2012-09-28 | ||
| KR20120109207 | 2012-09-28 | ||
| KR10-2012-0109207 | 2012-09-28 | ||
| KR20130017046 | 2013-02-18 | ||
| KR10-2013-0017046 | 2013-02-18 | ||
| PCT/KR2013/008459 WO2014046490A1 (ko) | 2012-09-19 | 2013-09-17 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078286A Division JP6708770B2 (ja) | 2012-09-19 | 2019-04-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500513A JP2016500513A (ja) | 2016-01-14 |
| JP2016500513A5 true JP2016500513A5 (enExample) | 2016-12-08 |
| JP6517692B2 JP6517692B2 (ja) | 2019-05-22 |
Family
ID=50341706
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532967A Active JP6517692B2 (ja) | 2012-09-19 | 2013-09-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2019078286A Active JP6708770B2 (ja) | 2012-09-19 | 2019-04-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2020088976A Active JP7007423B2 (ja) | 2012-09-19 | 2020-05-21 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2022000896A Active JP7328375B2 (ja) | 2012-09-19 | 2022-01-06 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2023127115A Active JP7627726B2 (ja) | 2012-09-19 | 2023-08-03 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078286A Active JP6708770B2 (ja) | 2012-09-19 | 2019-04-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2020088976A Active JP7007423B2 (ja) | 2012-09-19 | 2020-05-21 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2022000896A Active JP7328375B2 (ja) | 2012-09-19 | 2022-01-06 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2023127115A Active JP7627726B2 (ja) | 2012-09-19 | 2023-08-03 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9572900B2 (enExample) |
| EP (2) | EP3611184B1 (enExample) |
| JP (5) | JP6517692B2 (enExample) |
| KR (1) | KR102201429B1 (enExample) |
| CN (3) | CN104981478B (enExample) |
| ES (2) | ES2999332T3 (enExample) |
| TW (1) | TWI616531B (enExample) |
| WO (1) | WO2014046490A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169077A1 (ko) | 2012-05-11 | 2013-11-14 | 주식회사 카엘젬백스 | 악액질 예방 또는 치료용 조성물 |
| CN104507961B (zh) | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| CN110074997B (zh) | 2012-09-19 | 2022-07-08 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| TWI616530B (zh) * | 2012-09-19 | 2018-03-01 | 傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物（一） |
| WO2014046481A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| CN104981478B (zh) | 2012-09-19 | 2019-02-22 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
| JP6059405B2 (ja) | 2013-06-07 | 2017-01-11 | ジェムバックス アンド カエル カンパニー，リミティド | 癌の免疫学的治療に有用な生物学的マーカー |
| WO2014204281A1 (ko) | 2013-06-21 | 2014-12-24 | 주식회사 카엘젬백스 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
| ES2773296T3 (es) | 2013-10-23 | 2020-07-10 | Gemvax & Kael Co Ltd | Composición para tratar y prevenir la hiperplasia prostática benigna |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
| JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| JP6751097B2 (ja) | 2015-02-27 | 2020-09-02 | ジェムバックス アンド カエル カンパニー，リミティド | 聴力損傷予防用ペプチド及びそれを含む組成物 |
| KR102911237B1 (ko) | 2015-05-26 | 2026-01-13 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| EP3318265B1 (en) | 2015-07-02 | 2021-08-18 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
| EP4272829A3 (en) | 2016-04-07 | 2024-01-17 | Gemvax & Kael Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| WO2017192761A1 (en) * | 2016-05-03 | 2017-11-09 | The Regents Of The University Of Colorado, A Body Corporate | Propionyl-coa carboxylase compositions and uses thereof |
| KR102042758B1 (ko) * | 2017-06-28 | 2019-11-08 | 주식회사 엘지생활건강 | 경피투과도가 향상된 신경전달물질 조절 펩타이드 화장료 조성물 |
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| CA3229962A1 (en) | 2021-08-24 | 2023-03-02 | Peptidream Inc. | Human transferrin receptor-binding antibody-peptide conjugate |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846968B1 (en) * | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
| US5738996A (en) * | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| AR009416A1 (es) * | 1996-11-15 | 2000-04-12 | Amgen Inc | Nuevos genes que codifican proeinas de telomerasa |
| GB9705519D0 (en) | 1997-03-18 | 1997-05-07 | Anmat Technology Limited | Activation of peptides |
| EP0917579A1 (en) * | 1997-07-01 | 1999-05-26 | Cambia Biosystems LLC | Vertebrate telomerase genes and proteins and uses thereof |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US7078491B1 (en) | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| AUPR769701A0 (en) * | 2001-09-14 | 2001-10-11 | Li, He | Telomerase inhibitory peptides and uses thereof |
| CN1194007C (zh) * | 2001-10-25 | 2005-03-23 | 北京百泰博创医药科技有限公司 | P6a的代谢产物的分离、合成及其在医学中的应用 |
| WO2003038047A2 (en) | 2001-10-29 | 2003-05-08 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
| CA2481231A1 (en) * | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
| US8128908B2 (en) | 2004-04-30 | 2012-03-06 | University Of Florida Research Foundation, Inc. | Nanoparticles and their use for multifunctional bioimaging |
| WO2006108211A1 (en) * | 2005-02-25 | 2006-10-19 | The Murdoch Childrens Research Institute | Fragments of von willebrand factor a-related protein |
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| US20090068158A1 (en) * | 2005-12-09 | 2009-03-12 | Medin Jeffrey A | Thymidylate kinase mutants and uses thereof |
| WO2007069068A2 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| WO2007097561A1 (en) | 2006-02-20 | 2007-08-30 | Ewha University - Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
| CA2651917A1 (en) * | 2006-06-09 | 2007-12-13 | Bio Pur Ag | A method for the detection of enzymatic reactions |
| CA2676797C (en) * | 2007-01-29 | 2014-04-22 | Dae Woong Jo | Novel macromolecule transduction domains and methods for identification and uses thereof |
| US8378070B2 (en) * | 2007-03-12 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Peptides for the regulation of neurotransmitter sequestration and release |
| JP5170407B2 (ja) * | 2007-03-30 | 2013-03-27 | 国立大学法人九州工業大学 | 糖尿病合併症検査用試薬 |
| EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
| US8362209B2 (en) | 2007-08-23 | 2013-01-29 | University Of Medicine And Dentistry Of New Jersey | Telomerase reverse transcriptase variant |
| JP5734653B2 (ja) * | 2007-09-05 | 2015-06-17 | ジェネンテック， インコーポレイテッド | 生物学的に活性なｃ末端アルギニン含有ペプチド |
| US8252282B2 (en) | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| KR20100006939A (ko) * | 2008-07-10 | 2010-01-22 | 한국생명공학연구원 | 융합 단백질 전달을 통한 세포의 리프로그래밍 방법 |
| ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR101169030B1 (ko) * | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| JP5653214B2 (ja) | 2009-05-20 | 2015-01-14 | 東レ株式会社 | 細胞膜透過性ペプチド |
| EP2289558A1 (en) | 2009-08-25 | 2011-03-02 | KTB Tumorforschungsgesellschaft mbH | Bisphosphonate-prodrugs |
| PL2536830T3 (pl) * | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
| WO2011150494A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| CN102311493B (zh) * | 2010-07-02 | 2014-06-04 | 中国科学院上海生命科学研究院 | 一种抑制端粒酶活性的肽及其制备方法和应用 |
| KR101348284B1 (ko) | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| CN104507961B (zh) | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| ES2981865T3 (es) * | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| WO2014046481A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| CN104981478B (zh) | 2012-09-19 | 2019-02-22 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| CN110074997B (zh) * | 2012-09-19 | 2022-07-08 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| JP6059405B2 (ja) | 2013-06-07 | 2017-01-11 | ジェムバックス アンド カエル カンパニー，リミティド | 癌の免疫学的治療に有用な生物学的マーカー |
| KR102224965B1 (ko) | 2013-07-12 | 2021-03-09 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
| KR102911237B1 (ko) | 2015-05-26 | 2026-01-13 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| WO2017066349A1 (en) | 2015-10-13 | 2017-04-20 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
-
2013
- 2013-09-17 CN CN201380057894.1A patent/CN104981478B/zh active Active
- 2013-09-17 US US14/429,644 patent/US9572900B2/en active Active
- 2013-09-17 WO PCT/KR2013/008459 patent/WO2014046490A1/ko not_active Ceased
- 2013-09-17 KR KR1020157009511A patent/KR102201429B1/ko active Active
- 2013-09-17 EP EP19196538.3A patent/EP3611184B1/en active Active
- 2013-09-17 JP JP2015532967A patent/JP6517692B2/ja active Active
- 2013-09-17 ES ES19196538T patent/ES2999332T3/es active Active
- 2013-09-17 EP EP13838276.7A patent/EP2899201B1/en active Active
- 2013-09-17 ES ES13838276T patent/ES2758451T3/es active Active
- 2013-09-17 CN CN202111025572.1A patent/CN113699133B/zh active Active
- 2013-09-17 CN CN201710451503.4A patent/CN107312759B/zh active Active
- 2013-09-17 TW TW102133730A patent/TWI616531B/zh active
-
2016
- 2016-12-09 US US15/374,805 patent/US10245327B2/en active Active
-
2019
- 2019-02-12 US US16/273,689 patent/US11844845B2/en active Active
- 2019-04-17 JP JP2019078286A patent/JP6708770B2/ja active Active
-
2020
- 2020-05-21 JP JP2020088976A patent/JP7007423B2/ja active Active
-
2022
- 2022-01-06 JP JP2022000896A patent/JP7328375B2/ja active Active
-
2023
- 2023-08-03 JP JP2023127115A patent/JP7627726B2/ja active Active
- 2023-11-06 US US18/502,720 patent/US20240181090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500513A5 (enExample) | ||
| JP2016500648A5 (enExample) | ||
| JP2015530404A5 (enExample) | ||
| Chakraborti et al. | Self-assembly of ferritin: structure, biological function and potential applications in nanotechnology | |
| He et al. | Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer | |
| van der Meel et al. | Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status | |
| Altai et al. | Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors | |
| Wyatt et al. | Applications of pHLIP technology for cancer imaging and therapy | |
| Bhushan et al. | Ferritin nanocages: a novel platform for biomedical applications | |
| Ruan et al. | Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers | |
| Belletti et al. | Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin | |
| Jeevanandam et al. | Advancing aptamers as molecular probes for cancer theranostic applications—the role of molecular dynamics simulation | |
| JP2011037872A5 (enExample) | ||
| Costantini et al. | Update: peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications | |
| Wu et al. | Mannan-decorated lipid calcium phosphate nanoparticle vaccine increased the antitumor immune response by modulating the tumor microenvironment | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| HRP20121016T1 (hr) | Sredstva i postupci za upravljanje interferencijom proteina | |
| CN106366161A (zh) | 皮肤透过性肽 | |
| JP2010514779A5 (enExample) | ||
| Li et al. | Selective capture and recovery of monoclonal antibodies by self-assembling supramolecular polymers of high affinity for protein binding | |
| Kim et al. | Designing peptide bunches on nanocage for bispecific or superaffinity targeting | |
| Zou et al. | Expression, purification, and characterization of recombinant human L-chain ferritin | |
| CN103788211A (zh) | 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物 | |
| Wang et al. | Co‐delivery of Cell‐permeable Chimeric Apoptosis AVPIR8 Peptide/p53 DNA for Cocktail Therapy | |
| Gao et al. | Photothermal therapeutic gold nanoparticles loaded with PD-L1 siRNA enhanced killing of NSCLC cells by immune cells |